Lee-Cheng (LC) Liu, CEO of EirGenix, reflects on the evolution of Taiwan’s biotech sector and the company’s role within it as both a biologics CDMO and biosimilar developer. Liu discusses government-backed manufacturing initiatives, shifting global supply chains, and how regulatory changes are reshaping the biosimilar landscape. He also outlines EirGenix’s long-term growth strategy, from large-scale manufacturing expansion to global partnerships and capital market considerations.

Read the full article